Last day for subscription in the ongoing rights issue is October 19, 2020

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Hørsholm, Denmark, October 14, 2020 – In accordance with previous communication, Monday, October 19, 2020 is the last day for subscription in ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) share issue with preferential rights for the Company’s existing shareholders including warrants (the “Rights Issue” or the “Offering”). The last day for trading in unit rights is October 15, 2020. Shareholders with a share depository should check with their bank or nominee if they use an earlier end date for subscription.

In additon to previously communicated subscription undertakings of SEK 26.2m, Nyenburgh Holding B.V. who already has committed to subscribe for shares of SEK 11m and is a member of the guarantee consortium, has committed to subscribe for an additional amount of SEK 1,1m through aquisition of 140,000 unit rights from the chairman of the Board Martin Roland Jensen.

For complete information about the Offering, please refer to the prospectus that has been prepared by the Company and that has been approved by the SFSA. The prospectus is available on ExpreS2ion’s website (www.expres2ionbio.com) and Arctic Securities website (www.arctic.com/secse) and is also available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/). The prospectus is also passported to Denmark and thus also available for Danish investors.

Advisors

Arctic Securities AS, filial Sverige and Translution Capital ApS act as financial advisors to the Company in connection with the Offering. Arctic Securities is the Company’s issuing agent whereas Baker Mckenzie is the Company’s legal advisor in connection with the Offering.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

 

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail:
buf@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.